ArticlePloS one2014
Cyclic GMP-AMP displays mucosal adjuvant activity in mice.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Article
- Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026Review
- Elicitation of Protective Immune Responses Against Influenza Virus Following Intranasal Delivery of Fluzone or Flublok Vaccines.Vaccines · 2026Article
- Article
- STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Article
- PDE-stable 2'3'-cGAMP analogues, containing 5'-S-phosphorothioester linkage, as STING agonists.RSC medicinal chemistry · 2024Article
- Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway.Annals of medicine · 2023Article
- Review
- TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.International journal of biological sciences · 2023Article
- STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.Scientific reports · 2022Article
- STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma.Cell death & disease · 2022Article
- Development of an Intranasal Gel for the Delivery of a Broadly Acting Subunit Influenza Vaccine.ACS biomaterials science & engineering · 2022Article
- Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.Chemical reviews · 2022Review
- Immunomodulatory effects ofExperimental and therapeutic medicine · 2021Article
- Replacement of oxygen with sulfur on the furanose ring of cyclic dinucleotides enhances the immunostimulatory effectRSC medicinal chemistry · 2021Article
- The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development.Vaccines · 2021Review
- STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Double-edged effects of interferons on the regulation of cancer-immunity cycle.Oncoimmunology · 2021Review
Corrections and comments
- Erratum issuedCorrection: cyclic GMP-AMP displays mucosal adjuvant activity in mice.2015 · Ruecker, Christine [corrected to Rueckert, Christine]
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recently discovered mammalian enzyme cyclic GMP-AMP synthase produces cyclic GMP-AMP (cGAMP) after being activated by pathogen-derived cytosolic double stranded DNA. The product can stimulate STING-dependent interferon type I signaling. Here, we explore the efficacy of cGAMP as a mucosal adjuvant in mice. We show that cGAMP can enhance the adaptive immune response to the model antigen ovalbumin. It promotes antigen specific IgG and a balanced Th1/Th2 lymphocyte response in immunized mice. A characteristic of the cGAMP-induced immune response is the slightly reduced induction of interleukin-17 as a hallmark of Th17 activity--a distinct feature that is not observed with other cyclic di-nucleotide adjuvants. We further characterize the innate immune stimulation activity in vitro on murine bone marrow-derived dendritic cells and human dendritic cells. The observed results suggest the consideration of cGAMP as a candidate mucosal adjuvant for human vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.